Education
About Us
Working with TipRanks
Follow Us
uniQure N.V. (QURE)
NASDAQ:QURE
QURE Stock Chart & Stats
$26.06
-$1.39(-7.88%)
At close: 4:00 PM EST
$26.06
-$1.39(-7.88%)
Day’s Range― - ―
52-Week Range$5.50 - $71.50
Previous CloseN/A
Volume1.49M
Average Volume (3M)6.92M
Market Cap
$1.88B
Enterprise ValueN/A
Total Cash (Recent Filing)$376.97M
Total Debt (Recent Filing)$66.70M
Price to Earnings (P/E)―
Beta0.81
Next Earnings
Mar 02, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding61,603,770
10 Day Avg. Volume5,182,978
30 Day Avg. Volume6,918,341
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap0.00
Enterprise Value/Revenue0.00
Enterprise Value/Gross Profit0.00
Enterprise Value/Ebitda0.00
Forecast
1Y Price Target
$65.40Price Target Upside150.96% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering12
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical EfficacyAMT-130’s pivotal 3-year dataset demonstrates robust clinical efficacy, supporting a Biologics License Application filing.
Market PotentialThe data suggests a larger market opportunity and a higher probability of approval for AMT-130.
Regulatory PathUniQure's execution track-record inspires confidence in a viable regulatory path for AMT-130.
Bears Say
Regulatory DelayThe FDA's shift is a significant setback, leading to a likely delay in BLA timing for AMT-130.
Stock ReactionThe magnitude of the stock reaction—down ~60% pre-market—appears disproportionate relative to the program’s clinical dataset.
Uncertainty In ApprovalThe FDA indicated that data from the Phase 1/2 single-arm AMT-130 program may no longer be adequate as primary evidence for a BLA.
uniQure News
QURE FAQ
What was uniQure N.V.’s price range in the past 12 months?
uniQure N.V. lowest stock price was $5.50 and its highest was $71.50 in the past 12 months.
What is uniQure N.V.’s market cap?
uniQure N.V.’s market cap is $1.88B.
When is uniQure N.V.’s upcoming earnings report date?
uniQure N.V.’s upcoming earnings report date is Mar 02, 2026 which is in 115 days.
How were uniQure N.V.’s earnings last quarter?
Currently, no data Available
Is uniQure N.V. overvalued?
According to Wall Street analysts uniQure N.V.’s price is currently Undervalued.
Does uniQure N.V. pay dividends?
uniQure N.V. does not currently pay dividends.
What is uniQure N.V.’s EPS estimate?
uniQure N.V.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does uniQure N.V. have?
uniQure N.V. has 61,603,770 shares outstanding.
What happened to uniQure N.V.’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of uniQure N.V.?
Currently, no hedge funds are holding shares in QURE
uniQure Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$65.40 (150.96% Upside)
$65.40 (150.96% Upside)
Blogger Sentiment
Bullish
QURE Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 25.0K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 3.0%
Last 30 Days ▲ 15.9%
Last 30 Days ▲ 15.9%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
330.03%
12-Months-Change
Fundamentals
Return on Equity
-427.47%
Trailing 12-Months
Asset Growth
-19.97%
Trailing 12-Months
Company Description
uniQure N.V.
uniQure N.V., a gene therapy company, engages in the development of treatments for patients suffering from genetic and other devastating diseases. Its lead program is Etranacogene dezaparvovec (AMT-061), which is in Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also engages in developing AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease; AMT-060, which is in Phase I/II clinical trial for the treatment of hemophilia B; AMT-210, a product candidate for the treatment of Parkinson's disease; AMT-260 for temporal lobe epilepsy; AMT-240, a preclinical product candidate for the treatment of autosomal dominant Alzheimer's disease; and AMT-161 for the treatment of amyotrophic lateral sclerosis. uniQure N.V. was founded in 1998 and is headquartered in Amsterdam, the Netherlands.
QURE Earnings Call
Q2 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call highlighted significant regulatory and clinical advancements, particularly with AMT-130 and AMT-260, and a strong financial position. However, these positives were tempered by a notable decline in revenue and increased R&D expenses.View all QURE earnings summariesQURE Stock 12 Month Forecast
Average Price Target
$65.40
▲(150.96% Upside)
Technical Analysis
Rocket Pharmaceuticals
―
Spyre Therapeutics
―
Intellia Therapeutics
―
CureVac
―
Day One Biopharmaceuticals
―
Ownership Overview
2.24% Insiders
10.23% Mutual Funds
0.19% Other Institutional Investors
82.74% Public Companies and Individual Investors